Immune Response News and Research

RSS

Scientists discover novel defensive response to SARS-CoV-2

Scientists from Hokkaido University have discovered a novel defensive response to SARS-CoV-2 that involves the viral pattern recognition receptor RIG-I. Upregulating expression of this protein could strengthen the immune response in COPD patients.

21 May 2021

Facets of SARS-CoV-2 infection and animal models

A new study in the journal Frontiers in Cell and Developmental Biology discusses the ribonucleic acid (RNA) genome of the virus, and the mechanisms by which it establishes infection within the host cell. The researchers also summarize the development of animal models of COVID-19, which will both help understand the clinical features of the illness, and indicate new approaches for the treatment of the infection.

21 May 2021

Despite frequent vaccinations, COVID-19 could continue to cause recurrent waves and deaths

Covid-19 could continue to cause recurrent waves and deaths despite frequent vaccinations according to a new study from the University of East Anglia.

21 May 2021

Canopy Biosciences develops spatial proteomics assay for COVID-19

Canopy Biosciences, a Bruker Company, today announced the successful development of a new assay for examining immune response to COVID-19.

From Bruker Nano Surfaces and Metrology 21 May 2021

Researchers define immune determinants of protection against SARS-CoV-2 in mice

Researchers in the United States have conducted a preclinical study defining the roles that different arms of the immune system play in fighting primary infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as reinfection and infection following SARS-CoV-2 vaccination.

21 May 2021

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

A team of researchers recently cross-tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies to assess their neutralization activity against different variants. The team recently released their findings as a preprint on the medRxiv* server.

20 May 2021

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Researchers tested the vaccine candidate in mice with up to three doses and found it produces high levels of antibodies against both SARS-CoV-2 variants of concern and the original virus strain.

20 May 2021

Are COVID-19-related complications in children explained by abnormal immune responses?

A common theme in reports on COVID-19 around the world has been the large number of children who have not been infected or shown signs of disease. However, though the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes less acute infection in this age group, it is associated with a severe immune-mediated multisystemic illness called multisystem inflammatory syndrome in children (MIS-C).

20 May 2021

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

Now, a new report in the Journal of Thrombosis and Hemostasis reveals that timely diagnosis and treatment of this condition may prevent further morbidity and mortality, and enable the vaccine to be used widely with confidence.

20 May 2021

FDA reminds the public about the limitations of COVID-19 antibody

The following quote is attributed to Tim Stenzel, M.D., Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health.

20 May 2021

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

An interim report on a phase 2 clinical trial indicates both the safety and efficacy of a plant-produced virus-like particle vaccine candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vaccine candidate has shown an acceptable safety profile and high potency in inducing humoral and cellular immune responses in adults (18 – 64 years) and elderly (65 years and above) individuals. The report is currently available on the medRxiv* preprint server.

20 May 2021

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Researchers from Israel recently isolated a set of SARS-CoV-2 neutralizing monoclonal antibodies from blood samples of patients with severe COVID-19. They were the first to show that transgenic K18-hACE2 mice infected with lethal doses of SARS-CoV-2 can be fully protected by administering antibodies even 3 days after infection

19 May 2021

Potential immunotherapy may improve cognitive and behavioral functions after stroke

Specialized immune cells that accumulate in the brain in the days and weeks after a stroke promote neural functions in mice, pointing to a potential immunotherapy that may boost recovery after the acute injury is over, University of Pittsburgh School of Medicine neurologists found.

19 May 2021

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Scientists have recently investigated the dynamics of immune responses in elderly people who have received two doses of the Pfizer/BioNTech COVID-19 vaccine.

19 May 2021

Spike antibodies after vaccination with Pfizer and Oxford vaccines

A preprint discusses the results of a study of antibody responses to the first and second dose of currently available SARS-CoV-2 vaccines, Pfizer and Oxford.

19 May 2021

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

Researchers at St Jude Children’s Research Hospital found that toll-like receptor 2 detects the SARS-CoV-2 envelope protein-producing inflammatory cytokines.

19 May 2021

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

India’s surge in SARS-CoV-2 infections are linked to the new variants B.1.617 and B.1.618, with mutated spike proteins.

19 May 2021

Immune Response News and Research

Scientists discover novel defensive response to SARS-CoV-2

Facets of SARS-CoV-2 infection and animal models

Despite frequent vaccinations, COVID-19 could continue to cause recurrent waves and deaths

Canopy Biosciences develops spatial proteomics assay for COVID-19

Researchers define immune determinants of protection against SARS-CoV-2 in mice

Does cross-immunity exist between SARS-CoV-2 B.1.1.28 and P.1 variants?

A SARS-CoV-2 vaccine candidate based on B.1.351 spike trimer shows broad neutralizing capability

Are COVID-19-related complications in children explained by abnormal immune responses?

Early treatment may prevent clotting in COVID-19 vaccine-related thrombocytopenia

FDA reminds the public about the limitations of COVID-19 antibody

Plant-produced COVID-19 vaccine shows potent immunogenic profile in humans

Human monoclonal antibodies neutralize SARS-CoV-2 in an Fc-independent manner

Potential immunotherapy may improve cognitive and behavioral functions after stroke

Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval

Spike antibodies after vaccination with Pfizer and Oxford vaccines

Toll-like receptor 2 (TLR2) detects the SARS-CoV-2 envelope protein and generates inflammatory cytokines

The spike proteins of SARS-CoV-2 B.1.617 and B.1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies

Sequentia collaborated with Nextbiomics to obtain a novel immunization model against COVID-19

Presence of Anti-SARS-CoV-2 antibodies after 13 months of infection

How SARS-CoV-2 evolved from a bat-to a human-adapted virus

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News